Fees payable for medicinal products and companies
The Danish Medicines Agency is a public authority financed primarily by fees and charges from the companies, the reason being that the Danish parliament has decided that companies must pay for the reviews that the Danish Medicines Agency carries out for them. The fees and charges cover the costs of review, for example in relation to applications for authorisation of medicines, laboratory controls, inspections and monitoring of adverse reactions (side effects).
Below you will find the link to the new fee executive order, which entered into force on 1 May 2022. The Danish Medicines Agency expects that the executive order will be replaced by a new executive order in June 2022, which will include new fees as a result of the implementation of a new veterinary regulation.